Reversine exhibits antineoplastic activity in JAK2V617F-positive myeloproliferative neoplasms
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Reversine exhibits antineoplastic activity in JAK2V617F-positive myeloproliferative neoplasms
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-07-09
DOI
10.1038/s41598-019-46163-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
- (2018) Tiziano Barbui et al. LEUKEMIA
- Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton
- (2018) Michel O. Steinmetz et al. TRENDS IN CELL BIOLOGY
- Reversine inhibits Colon Carcinoma Cell Migration by Targeting JNK1
- (2018) Mohamed Jemaà et al. Scientific Reports
- A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies
- (2017) Ankit C. Borisa et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- STAT5BN642H is a driver mutation for T cell neoplasia
- (2017) Ha Thi Thanh Pham et al. JOURNAL OF CLINICAL INVESTIGATION
- Reversine triggers mitotic catastrophe and apoptosis in K562 cells
- (2016) Ana Paula Nunes Rodrigues Alves et al. LEUKEMIA RESEARCH
- CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms
- (2015) Sara C. Meyer et al. CANCER CELL
- Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition
- (2015) Qiang Jeremy Wen et al. NATURE MEDICINE
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells
- (2015) João Agostinho Machado-Neto et al. Oncotarget
- JAK2V617F Drives Mcl-1 Expression and Sensitizes Hematologic Cell Lines to Dual Inhibition of JAK2 and Bcl-xL
- (2015) Jun Guo et al. PLoS One
- Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F
- (2013) Karoline Gäbler et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- The synthetic purine reversine selectively induces cell death of cancer cells
- (2012) Marco Piccoli et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reversine induces cell cycle arrest, polyploidy, and apoptosis in human breast cancer cells
- (2012) Chin-Ho Kuo et al. Breast Cancer
- Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis
- (2011) Vibe Skov et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells
- (2011) Kazuya Sumi et al. FEBS LETTERS
- Aurora B potentiates Mps1 activation to ensure rapid checkpoint establishment at the onset of mitosis
- (2011) Adrian T. Saurin et al. Nature Communications
- Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms
- (2010) N. H. Thoennissen et al. BLOOD
- The c-Jun N-terminal kinase JNK functions upstream of Aurora B to promote entry into mitosis
- (2010) Kutluk Oktay et al. CELL CYCLE
- Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine
- (2010) Stefano Santaguida et al. JOURNAL OF CELL BIOLOGY
- JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
- (2010) A Pardanani et al. LEUKEMIA
- Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity
- (2010) Douglas W McMillin et al. NATURE MEDICINE
- STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease
- (2009) G. Li et al. BLOOD
- Autonomous growth potential of leukemia blast cells is associated with poor prognosis in human acute leukemias
- (2009) Ying Yan et al. Journal of Hematology & Oncology
- Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells
- (2008) A. M. D'Alise et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started